ARTV

3.7801.31%
GD

Gines Diego Miralles

President and Head of Research & Development

Dr. Gines Diego Miralles, M.D., is Director of Contineum Therapeutics, Inc. from March 14, 2025. He serves as Chair of the Board at ArrePath, Inc. since June 2025. Dr. Miralles has served as Chief Executive Officer at AZURNA Therapeutics, Inc., a private pharmaceutical development company, since January 2024. From December 2020 to September 2022, Dr. Miralles was Chief Executive Officer at Laronde Inc., an early-stage biotechnology company. Dr. Miralles served on the board of directors of Artiva Biotherapeutics, Inc., a publicly traded biotechnology company, since May 2024 until May 18, 2026 and is its President and Head of Research & Development since May 18, 2026. Dr. Miralles has also been a member of the board of directors at Rady Children's Institute for Genomic Medicine since 2008 and served as a member of the board of directors at NeuBase Therapeutics, Inc., a public biopharmaceutical company, from April 2019 to April 2021. He had been Chief Executive Officer at Vividion Therapeutics, Inc. since September 7, 2017 September 2020. Dr. Miralles served as President of Adaptive Therapeutics, Inc. since March 15, 2016. Dr. Miralles served as the Global Head for Johnson & Johnson Innovation. He was founder of the Johnson & Johnson Innovation Centers and JLABS, a best-in-class corporate incubator for entrepreneurs in the healthcare and life sciences industries. Dr. Miralles also headed an entrepreneurial team within the Janssen Pharmaceutical Companies of Johnson & Johnson that created integrated care businesses and enabling technologies to transform the healthcare experience, improve outcomes and reduce healthcare costs. He headed the Janssen Research and Early Development unit in La Jolla, California focused in pharmaceutical discoveries and early proof of concept clinical development. He served as an Independent Director of NeuBase Therapeutics, Inc. since July 12, 2019 until March 31, 2021. Dr. Miralles served as the head of External Innovation for the immunology therapeutic area at Johnson & Johnson Pharmaceutical Research & Development. Dr. Miralles was responsible for expanding the immunology R&D network through external partnerships to increase research/development capabilities and the immunology portfolio. He served as head of the Johnson & Johnson Pharmaceutical Research and Development (PRD) Discovery site in San Diego, Calif., since August 2008. He was also on the faculty at Duke University, Durham, NC, from 1993 to 1998. He continued his academic appointment and clinical HIV practice at Duke from 1993 to 2005. He joined Triangle Pharmaceuticals as associate director and then director, team leader, DMP-450, from 1998 to 2000. He was then with Trimeris as director/senior director, clinical trials, Clinical Team Leader T-1249, from 2000 to 2005. He joined Tibotec/Johnson & Johnson in Belgium in June 2005 and served as its Vice President of Global Clinical Development since June 2005, where he oversaw the regulatory approval of Prezista and Intelence and was on Tibotec/Johnson & Johnson's board. He serves as Member of Advisory Council at Capsule Technologies, Inc. (Formerly, Qualcomm Life, Inc.). He serves as an Adjunct Professor in the Department of Pharmacology at the University of California San Diego. He served as an Assistant Professor at Duke University Medical Center, serving as a scientist and an Infectious Disease physician. From Universidad de Buenos Aires, Argentina, he completed his residency in internal medicine at the Mayo Clinic in Rochester, Minn. from 1987 to 1990 and his fellowship in infectious diseases at Cornell University-New York Hospital from 1990 to 1992. He was attending in charge at The AIDS Clinical Trial Unit, Beth Israel Medical Center, New York in 1993. Dr. Miralles received his M.D. from the Universidad de Buenos Aires, Argentina. He served as a Member of Scientific Advisory Board at Cypher Genomics Inc.

Positions